Clinical Trials Browser

Phase 3 × Pathologic Complete Response × cc-486 × Clear all

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

472 enrolled 24 charts 2 FDA

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute